Shares of Nektar Therapeutics and Mineralys Therapeutics have experienced a significant surge in their stock prices recently, with the potential for further growth. Nektar is currently in the process of developing an experimental treatment for eczema, while Mineralys is working on a drug that could benefit millions of patients dealing with high blood pressure.
Nektar Therapeutics has seen a remarkable 108% increase in its stock price from August 18 to September 18. This surge can be attributed to the positive results from its lead candidate, rezpegaldesleukin, which showed promising outcomes in a phase 2b study for patients with moderate to severe eczema. The results indicated a 30% improvement compared to a placebo, positioning the drug as a potential competitor to the blockbuster eczema treatment, Dupixent. Nektar’s stock has soared as the candidate continues to show improvements even beyond the initial 16-week trial period.
On the other hand, Mineralys Therapeutics witnessed a 155% increase in its stock price from the closing bell on August 18 to midday on September 19. This growth was fueled by positive clinical trial results for its lead candidate, lorundrostat, an experimental drug targeting aldosterone to treat hypertension. The phase 3 trial showed a significant reduction in systolic blood pressure compared to a placebo, positioning the drug as a potential blockbuster treatment for patients with hard-to-control blood pressure.
Mineralys plans to file an application with the FDA by the end of 2025 or early 2026, indicating its commitment to bringing the drug to market. With a strong cash position and successful fundraising efforts, the company is well-positioned to support its drug development efforts.
While both companies show promise in their respective drug pipelines, investors should be cautious as these stocks carry inherent risks. Nektar Therapeutics, despite its potential for a blockbuster eczema treatment, has yet to start a phase 3 program. Similarly, Mineralys Therapeutics faces competition from other drug developers in the hypertension space, which could impact its market position.
In conclusion, the biotechnology sector continues to offer exciting investment opportunities with companies like Nektar Therapeutics and Mineralys Therapeutics showing significant potential for growth. However, investors should conduct thorough research and consider the risks involved before making investment decisions in these volatile markets.
